Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy

27 Mar 2009

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Neuroblastoma Research and Treatments
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19327829
DOI: 10.1016/j.leukres.2009.02.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancyPMID 19327829Read ↗

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.Semantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

Mutation-guided therapeutics.Semantic proximity Read ↗

Fully human CD19-specific chimeric antigen receptors for T-cell therapySemantic proximity Read ↗

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CARSemantic proximity Read ↗

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cellsSemantic proximity Read ↗

Adoptive Therapy With Chimeric Antigen Receptor–Modified T Cells of Defined Subset CompositionSemantic proximity Read ↗

Genetically modified T cells in cancer therapy: opportunities and challengesSemantic proximity Read ↗

Targeting cancer with bispecific antibodies.Semantic proximity Read ↗

Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen ReceptorSemantic proximity Read ↗

Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.